Pathology News and Research

RSS

Pathology is the study and diagnosis of disease through examination of organs, tissues, bodily fluids, and whole bodies (autopsies). The term also encompasses the related scientific study of disease processes, called General pathology. Medical pathology is divided in two main branches, Anatomical pathology and Clinical pathology. Veterinary pathology is concerned with animal disease whereas Phytopathology is the study of plant diseases.

Prometheus, UCLA collaborate to identify biological markers of mucosal healing in IBD

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and The Regents of the University of California, Los Angeles campus, today announced the execution of an exclusive research agreement that will focus on the identification of biological markers of mucosal healing in patients with Inflammatory Bowel Disease (IBD). The research will be led by Dr. Jonathan Braun, Chair of the Department of Pathology and Laboratory Medicine and a professor of molecular and medical pharmacology, UCLA David Geffen School of Medicine.

10 Dec 2010

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib (Tarceva®).

10 Dec 2010

Caliper to acquire CRi for $20.0 million

Caliper Life Sciences, Inc., a leading provider of products and services for drug discovery research, today announced that it has entered into a definitive agreement to acquire privately-held Cambridge Research & Instrumentation, Inc. (CRi) for approximately $20.0 million, including net debt. CRi's patented preclinical and tissue-based multiplexed analysis systems will expand Caliper's life sciences tools portfolio, particularly as it bridges into clinical research, pathology and clinical market applications.

10 Dec 2010

Researchers target MIC-1 protein to halt growth of melanoma tumors

Halting the growth of melanoma tumors by targeting the MIC-1 protein that promotes blood vessel development in tumors may lead to better treatment of this invasive and deadly cancer, according to Penn State College of Medicine researchers in The Foreman Foundation Research Laboratory.

10 Dec 2010

Chinese study examines association between alcohol intake, CAD

Among a large number of Chinese men presenting with chest pain or EKG changes, sequential subjects undergoing cardiac angiography were evaluated for obstructive coronary artery disease lesions according to their reported recent alcohol intake. The study population consisted of 1,476 consecutive men 36 to 84 years of age; participants were categorized as nondrinkers, light drinkers, moderate drinkers, or heavy drinkers.

10 Dec 2010

Clarient introduces Mammostrat test to quantify likelihood of breast cancer recurrence

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of Mammostrat, a patented, novel test designed to help quantify the likelihood of recurrence of breast cancer following surgery and initial treatment.

9 Dec 2010

Dogs help understand primary ciliary dyskinesia

A dog is mankind's best friend : the old saying has once again been borne out through a medical discovery concerning the genetic origins of primary ciliary dyskinesia (PCD). In using dogs as a research model in the framework of the European LUPA project, a team from the University of Liège's GIGA-Research Unit has been able to bring to light new mutations in a specific gene responsible for the development of the disease in human beings.

9 Dec 2010

New objective criteria for evaluating hemostatic efficacy in treatment of VWD

Octapharma USA researchers presented new stringent, objective criteria used in the evaluation of hemostatic efficacy in the treatment of von Willebrand disease and reported on their application of these criteria in clinical trials during the recently completed National Hemophilia Foundation Annual Meeting.

9 Dec 2010

New sensitive blood test could determine unrecognized heart disease

A more sensitive version of a blood test typically used to confirm that someone is having a heart attack could indicate whether a seemingly healthy, middle-aged person has unrecognized heart disease and an increased risk of dying, UT Southwestern Medical Center researchers have found.

7 Dec 2010

$Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010$

Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010

EntreMed, Inc., today announced the presentation of data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor. Data from the Phase 1 studies with ENMD-2076 in patients with multiple myeloma and relapsed or refractory leukemia were presented by EntreMed investigators during poster sessions at the 2010 American Society of Hematology Annual Meeting being held December 4-7 in Orlando, Florida.

7 Dec 2010

Clinical trial results of ACY-1215 in multiple myeloma published in scientific journal of ASH

Acetylon Pharmaceuticals today announced the publication of favorable results of preclinical safety and efficacy testing of its oral selective HDAC6 inhibitor drug candidate, ACY-1215, in multiple myeloma.

7 Dec 2010

NanoString secures exclusive worldwide license to develop products for breast cancer intrinsic subtyping

NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced it has secured an exclusive worldwide license from Bioclassifier, LLC to develop in vitro diagnostic and research products for breast cancer intrinsic subtyping.

From NanoString Technologies 7 Dec 2010

$Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL$

Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

Allos Therapeutics, Inc. today reported new analysis of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida.

6 Dec 2010

Elsevier announces title change for Cancer Genetics and Cytogenetics journal

Elsevier, the world's leading publisher of scientific, technical and medical information, announced today that its highly respected Cancer Genetics and Cytogenetics journal is changing its title to Cancer Genetics and has named Dr. Jaclyn A. Biegel as editor-in-chief.

6 Dec 2010

Patients with H1N1 flu die due to over-reactive immune response: Research

On November 19, Jason Martin returned to the Medical Intensive Care Unit at Vanderbilt University Medical Center for the first time since he nearly died there during last year's H1N1 flu pandemic. The tall and burly Warren County, TN, ambulance worker - a 30-year-old, father of three young children - broke down and hugged some of the nurses he recognized.

6 Dec 2010

$Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting$

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

Allos Therapeutics, Inc. today reported new analyses of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma at the 52nd American Society of Hematology Annual Meeting held in Orlando, Florida.

6 Dec 2010

Increase in suicide rates underestimated

Ian Rockett, Ph.D, M.P.H., professor of epidemiology and associate chair of the West Virginia University Department of Community Medicine, isn't buying the story the suicide numbers are telling.

4 Dec 2010

Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1/2 clinical study of NP002 for the treatment of dyskinesias (muscle movement disorders) resulting from levodopa therapy for patients with Parkinson's disease.

4 Dec 2010

Clarient extends pending offer, files amendment to Solicitation/Recommendation Statement

Clarient, Inc. announced today the extension of the current pending offer by Crane Merger Sub, Inc., an indirect wholly-owned subsidiary of General Electric Company to acquire all of the outstanding shares of capital stock of the Company.

4 Dec 2010

URMC's Cone Beam CT scanner studies presented at RSNA 2010

While questions persist about the best ways to detect breast cancer early, a CT imaging system developed at the University of Rochester Medical Center and first unveiled five years ago is in a better position today to enter the fray -- at least in a supporting role to conventional mammography.

4 Dec 2010

Pathology News and Research

Further Reading

Prometheus, UCLA collaborate to identify biological markers of mucosal healing in IBD

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

Caliper to acquire CRi for $20.0 million

Researchers target MIC-1 protein to halt growth of melanoma tumors

Chinese study examines association between alcohol intake, CAD

Clarient introduces Mammostrat test to quantify likelihood of breast cancer recurrence

Dogs help understand primary ciliary dyskinesia

New objective criteria for evaluating hemostatic efficacy in treatment of VWD

New sensitive blood test could determine unrecognized heart disease

Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010

Clinical trial results of ACY-1215 in multiple myeloma published in scientific journal of ASH

NanoString secures exclusive worldwide license to develop products for breast cancer intrinsic subtyping

Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

Elsevier announces title change for Cancer Genetics and Cytogenetics journal

Patients with H1N1 flu die due to over-reactive immune response: Research

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

Increase in suicide rates underestimated

Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease

Clarient extends pending offer, files amendment to Solicitation/Recommendation Statement

URMC's Cone Beam CT scanner studies presented at RSNA 2010

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News